Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Disease area: Interstitial lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Varghese (Rochester, United States of America), G. Johnson (Rochester, United States of America), P. Eiken (Rochester, United States of America), P. Tobias (Rochester, United States of America). Late Breaking Abstract - Rituximab limits the progression of fibrosing mediastinitis. 5325

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition Source: International Congress 2018 – New methods for diagnosing and treating lung diseases Year: 2018 Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia Source: Virtual Congress 2021 – Diagnosis and management of COVID-19 Year: 2021 Late Breaking Abstract - Acute multi-organ symptoms predict long COVID Source: Virtual Congress 2021 – Diagnosis and management of COVID-19 Year: 2021 Late Breaking Abstract - Fully automated airway measurement correlates with radiological disease progression in Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Remote monitoring of respiratory patients Year: 2021 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Systemic ferritin is an early disease biomarker for silicosis patients Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Late Breaking Abstract - Promising results of the infliximab biosimilar Inflectra® in severe sarcoidosis patients Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Late Breaking Abstract - Plasma cells and endothelitis in COVID-19 lung pathology Source: Virtual Congress 2020 – Covering COVID - the best abstracts Year: 2020 Late Breaking Abstract - Frequency and characteristics of TB relapses Source: International Congress 2017 – Late-breaking studies in pulmonary diseases Year: 2017 Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Increased risk of pulmonary embolism in patients with radiological severe COVID-19 pneumonia Source: Virtual Congress 2020 – COVID-19 clinical studies Year: 2020 Late Breaking Abstract - Defining a severe asthma super-responder: findings from a Delphi process Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Late Breaking Abstract - Asthma control in preschool and subsequent disease remission Source: International Congress 2019 – Asthma and the world Year: 2019 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Late Breaking Abstract - Value of the interleukin profile can be an objective standart for control  the tactics of managing patients with bronchiolitis Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Late Breaking Abstract - Air pollution and IPF acute exacerbation Source: International Congress 2017 – The wide spectrum of ILDs Year: 2017 Late Breaking Abstract - Study of natural autoantibodies in rheumatoid arthritis patients with pulmonary involvement Source: International Congress 2017 – Late-breaking studies in pulmonary diseases Year: 2017 B-lymphocyte targeted therapy for patients with progressive fibrosing mediastinitis Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014